BR0016883A - Processos para detecção de proteìnas amiloidogênicas - Google Patents
Processos para detecção de proteìnas amiloidogênicasInfo
- Publication number
- BR0016883A BR0016883A BR0016883-1A BR0016883A BR0016883A BR 0016883 A BR0016883 A BR 0016883A BR 0016883 A BR0016883 A BR 0016883A BR 0016883 A BR0016883 A BR 0016883A
- Authority
- BR
- Brazil
- Prior art keywords
- aggregation
- assay
- amyloid
- peptide
- amyloid peptide
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
"PROCESSO PARA DETECçãO DE PROTEìNAS AMILOIDOGêNICAS". A invenção refere-se a um processo/ensaio para a detecção de várias formas agregadas de um peptídeo amilóide que usa sondas espectroscópicas específicas a amilóide, tais como vermelho de Congo e análogos relacionados. Tal ensaio poderia ser usado para avaliar o estado de agregação do peptídeo na presença de outros inibidores potenciais de fibrilogêne-se, fornecendo o modelo útil por meio do qual testa inibidores de agregação em modelos in vitro. Os resultados de tal ensaio podem ser úteis na determinação no estágio em que se pode intervir no processo de agregação para reduzir a toxicidade do peptídeo em células neuronais. Em exemplos específicos, o dicroísmo circular, a absorção de UV e a espectroscopia de fluorescência são cada um usados para avaliar a forma de agregação do peptídeo beta-amilóide.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/474,970 US6399314B1 (en) | 1999-12-29 | 1999-12-29 | Methods of detection of amyloidogenic proteins |
PCT/US2000/032693 WO2001050134A2 (en) | 1999-12-29 | 2000-12-01 | Methods of detection of amyloidogenic proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0016883A true BR0016883A (pt) | 2002-10-01 |
Family
ID=23885720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0016883-1A BR0016883A (pt) | 1999-12-29 | 2000-12-01 | Processos para detecção de proteìnas amiloidogênicas |
Country Status (21)
Country | Link |
---|---|
US (1) | US6399314B1 (pt) |
EP (1) | EP1242822B1 (pt) |
JP (1) | JP2003519383A (pt) |
KR (1) | KR20020070470A (pt) |
CN (1) | CN1211661C (pt) |
AT (1) | ATE399323T1 (pt) |
AU (1) | AU774377B2 (pt) |
BR (1) | BR0016883A (pt) |
CA (1) | CA2395789C (pt) |
DE (1) | DE60039310D1 (pt) |
DK (1) | DK1242822T3 (pt) |
EA (1) | EA005582B1 (pt) |
ES (1) | ES2309003T3 (pt) |
HK (1) | HK1046550B (pt) |
IL (2) | IL150080A0 (pt) |
MX (1) | MXPA02006362A (pt) |
NO (1) | NO20023163L (pt) |
NZ (1) | NZ519612A (pt) |
PL (1) | PL356813A1 (pt) |
PT (1) | PT1242822E (pt) |
WO (1) | WO2001050134A2 (pt) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US20030147882A1 (en) * | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
DE19923811C1 (de) * | 1999-05-20 | 2000-12-07 | Robert Koch Inst | Verfahren zur Diagnose TSE-induzierter Veränderungen in Geweben mittels Infrarotspektroskopie |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
US6689753B1 (en) * | 1999-11-05 | 2004-02-10 | Axonyx, Inc. | β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide |
WO2002016951A2 (en) | 2000-08-21 | 2002-02-28 | The General Hospital Corporation | Methods for diagnosing a neurodegenerative condition |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
TWI255272B (en) * | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
NZ531337A (en) * | 2001-04-27 | 2006-05-26 | Gen Hospital Corp | Ocular diagnosis of alzheimer's disease |
US7166471B2 (en) * | 2001-05-31 | 2007-01-23 | Arete Associates | Misfolded protein sensor method in body fluids |
US20050026165A1 (en) | 2001-05-31 | 2005-02-03 | Cindy Orser | Detection of conformationally altered proteins and prions |
AU2002360696A1 (en) * | 2001-12-21 | 2003-07-30 | Ilex Oncology, Inc. | Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis |
MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
US20070003552A1 (en) * | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
EP1380290A1 (en) * | 2002-07-09 | 2004-01-14 | Universitair Medisch Centrum Utrecht | Cross-beta structure pathway and its therapeutic relevance |
TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
US20050048539A1 (en) * | 2003-06-13 | 2005-03-03 | The General Hospital Corporation | Methods to monitor molecule conformation and molecule/molecule proximity |
SE0401219D0 (sv) * | 2004-05-10 | 2004-05-10 | Biochromix Ab | Metoder för detektera konformationsförändringar eller aggregering hos proteiner med hjälp av konjugerade polyelektrolyter |
US20060057671A1 (en) * | 2004-09-10 | 2006-03-16 | Orser Cindy S | Immobilized probes and methods of detecting conformationally altered prion proteins |
WO2006066089A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
PE20061401A1 (es) * | 2004-12-15 | 2006-12-23 | Neuralab Ltd | ANTICUERPOS Aß PARA MEJORAR LA COGNICION |
ES2396555T3 (es) * | 2004-12-15 | 2013-02-22 | Janssen Alzheimer Immunotherapy | Anticuerpos que reconocen péptido beta amiloide |
JP4568840B2 (ja) * | 2004-12-28 | 2010-10-27 | 国立大学法人金沢大学 | アルツハイマー病の検査方法 |
WO2006069697A1 (en) * | 2004-12-30 | 2006-07-06 | F. Hoffmann-La Roche Ag | Colorimetrically assessing peptide characteristics |
US8372593B2 (en) * | 2005-02-15 | 2013-02-12 | Adlyfe, Inc. | Method for detecting misfolded proteins and prions |
US20090202980A1 (en) * | 2005-03-21 | 2009-08-13 | Crossbeta Biosciences B.V. | Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation |
ATE554394T1 (de) * | 2005-07-13 | 2012-05-15 | Crossbeta Biosciences Bv | Cross-beta-struktur-bindende verbindungen |
CA2615020A1 (en) * | 2005-07-13 | 2007-01-18 | Crossbeta Biosciences B.V. | Adjuvation through cross-.beta. structure |
US20070015133A1 (en) * | 2005-07-13 | 2007-01-18 | Umc Utrecht Holding B.V. | Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein |
US8114832B2 (en) * | 2005-07-13 | 2012-02-14 | Crossbeta Biosciences B.V. | Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
WO2009017467A1 (en) | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
BRPI0714930A2 (pt) * | 2006-07-28 | 2013-05-21 | Adlyfe Inc | sondas peptÍdicas para fins diagnàsticos e terapÊuticos |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
EP2058001A1 (en) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Enhancement of immunogenicity of antigens |
EP2058000A1 (en) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Immunogenic compositions capable of activating T cells |
US20100021390A1 (en) * | 2008-03-17 | 2010-01-28 | The Research Foundation Of State University Of New York | Fluorescent Analogs Of The Islet Amyloid Polypeptide |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
RU2509155C1 (ru) * | 2012-10-25 | 2014-03-10 | Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук | Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии |
GB201303507D0 (en) * | 2013-02-27 | 2013-04-10 | Hollfelder Florian | Assays |
US9588129B2 (en) * | 2013-03-15 | 2017-03-07 | Amira Medical Technologies Inc. | Methods for analyzing blood to detect diseases associated with abnormal protein aggregation |
CN104803993B (zh) * | 2015-03-01 | 2017-11-03 | 四川大学 | 一种具有Aβ亲和力的荧光化合物及其用途 |
CN105651752B (zh) * | 2016-02-26 | 2019-04-12 | 国家纳米科学中心 | 淀粉样蛋白的检测方法 |
CN105717182B (zh) * | 2016-03-10 | 2018-05-11 | 中南大学 | 一种用于同步检测淀粉样多肽单体和聚集体的生物传感器及其构建方法和应用 |
WO2018136910A1 (en) * | 2017-01-23 | 2018-07-26 | Rensselaer Polytechnic Institute | Systems and methods for binding amyloid fibrils using fluorescent protein |
CN108489941B (zh) * | 2018-01-31 | 2021-07-27 | 吉林大学 | 溴酚蓝在作为检测牛胰岛素淀粉样纤维探针和作为牛胰岛素淀粉样纤维抑制剂方面的应用 |
US20210165001A1 (en) * | 2018-08-03 | 2021-06-03 | The University Of Hong Kong | Compositions and methods for detection and imaging of amyloid fibrils, amyloid plaques, rna, and nucleoli |
CN111504957B (zh) * | 2019-01-31 | 2021-12-03 | 吉林大学 | 一种维多利亚蓝b及其衍生物在制备异构化蛋白的探针或抑制剂中的应用 |
KR102258048B1 (ko) * | 2019-05-30 | 2021-05-31 | 주식회사 캔티스 | 아밀로이드 베타 올리고머의 검출 방법 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2013396A1 (en) * | 1989-04-05 | 1990-10-05 | Dennis J. Selkoe | Diagnostic method for alzheimer's disease: examination of non-neural tissue |
US5276059A (en) | 1992-07-10 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of diseases associated with amyloid formation |
AU6728396A (en) | 1995-08-17 | 1997-03-12 | Ontario Cancer Institute, The | Protein fibril assembly assay |
JPH0995444A (ja) * | 1995-10-02 | 1997-04-08 | Teijin Ltd | アミロイド蛋白凝集阻害剤 |
JP2001515044A (ja) | 1997-08-14 | 2001-09-18 | ザ・レジェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア | 蛍光アミロイドAβペプチドとその使用 |
JP4537577B2 (ja) * | 1998-03-13 | 2010-09-01 | ユニバーシティ・オブ・ワシントン | アルツハイマー病及びプリオン病の治療に関する抗プラーク療法を特定するコンゴ好染性マルタ十字形アミロイドプラークのinvitroにおける形成 |
-
1999
- 1999-12-29 US US09/474,970 patent/US6399314B1/en not_active Expired - Fee Related
-
2000
- 2000-12-01 EP EP00980905A patent/EP1242822B1/en not_active Expired - Lifetime
- 2000-12-01 IL IL15008000A patent/IL150080A0/xx active IP Right Grant
- 2000-12-01 DK DK00980905T patent/DK1242822T3/da active
- 2000-12-01 ES ES00980905T patent/ES2309003T3/es not_active Expired - Lifetime
- 2000-12-01 AT AT00980905T patent/ATE399323T1/de not_active IP Right Cessation
- 2000-12-01 PL PL00356813A patent/PL356813A1/xx not_active Application Discontinuation
- 2000-12-01 BR BR0016883-1A patent/BR0016883A/pt not_active Application Discontinuation
- 2000-12-01 CA CA2395789A patent/CA2395789C/en not_active Expired - Fee Related
- 2000-12-01 DE DE60039310T patent/DE60039310D1/de not_active Expired - Lifetime
- 2000-12-01 EA EA200200722A patent/EA005582B1/ru not_active IP Right Cessation
- 2000-12-01 KR KR1020027008505A patent/KR20020070470A/ko not_active IP Right Cessation
- 2000-12-01 NZ NZ519612A patent/NZ519612A/en unknown
- 2000-12-01 CN CNB008178658A patent/CN1211661C/zh not_active Expired - Fee Related
- 2000-12-01 MX MXPA02006362A patent/MXPA02006362A/es active IP Right Grant
- 2000-12-01 PT PT00980905T patent/PT1242822E/pt unknown
- 2000-12-01 WO PCT/US2000/032693 patent/WO2001050134A2/en active IP Right Grant
- 2000-12-01 JP JP2001550033A patent/JP2003519383A/ja active Pending
- 2000-12-01 AU AU18103/01A patent/AU774377B2/en not_active Ceased
-
2002
- 2002-06-06 IL IL150080A patent/IL150080A/en not_active IP Right Cessation
- 2002-06-28 NO NO20023163A patent/NO20023163L/no not_active Application Discontinuation
- 2002-11-08 HK HK02108122.2A patent/HK1046550B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ES2309003T3 (es) | 2008-12-16 |
IL150080A0 (en) | 2002-12-01 |
CN1415074A (zh) | 2003-04-30 |
DK1242822T3 (da) | 2008-09-29 |
NZ519612A (en) | 2004-04-30 |
EP1242822B1 (en) | 2008-06-25 |
JP2003519383A (ja) | 2003-06-17 |
CA2395789A1 (en) | 2001-07-12 |
HK1046550A1 (en) | 2003-01-17 |
WO2001050134A2 (en) | 2001-07-12 |
AU1810301A (en) | 2001-07-16 |
NO20023163L (no) | 2002-08-27 |
EP1242822A2 (en) | 2002-09-25 |
MXPA02006362A (es) | 2002-11-29 |
PT1242822E (pt) | 2008-09-29 |
HK1046550B (zh) | 2008-12-19 |
WO2001050134A3 (en) | 2002-06-27 |
AU774377B2 (en) | 2004-06-24 |
EA200200722A1 (ru) | 2002-12-26 |
CA2395789C (en) | 2010-03-30 |
ATE399323T1 (de) | 2008-07-15 |
US6399314B1 (en) | 2002-06-04 |
KR20020070470A (ko) | 2002-09-09 |
NO20023163D0 (no) | 2002-06-28 |
EA005582B1 (ru) | 2005-04-28 |
CN1211661C (zh) | 2005-07-20 |
PL356813A1 (en) | 2004-07-12 |
IL150080A (en) | 2009-02-11 |
DE60039310D1 (de) | 2008-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0016883A (pt) | Processos para detecção de proteìnas amiloidogênicas | |
Kommaddi et al. | Aβ mediates F-actin disassembly in dendritic spines leading to cognitive deficits in Alzheimer's disease | |
Zareba-Koziol et al. | Stress-induced Changes in the S-palmitoylation and S-nitrosylation of Synaptic Proteins*[S] | |
Strucksberg et al. | Proteasomal activity in skeletal muscle: a matter of assay design, muscle type, and age | |
Solberg et al. | A five-year follow-up study of antioxidants, oxidative stress and polyunsaturated fatty acids in schizophrenia | |
ES2422295T3 (es) | Aparato y procedimiento para la concentración y representación de partículas de ensayo | |
DK0679251T3 (da) | Fremgangsmåde og apparat til vurdering af biopolymerers fitness | |
ATE443775T1 (de) | Hif-prolylhydroxylase-aktivitätstest | |
ATE494393T1 (de) | Testverfahren für nukleinsäuren mittels fluoreszenz | |
BRPI0812875A2 (pt) | " método pra identificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, anticorpo específico para proteína ligante de heparina, método pra reduzir o risco de um indivíduo desenvolver sépsis severa, e, kit de teste ". | |
Abrigo et al. | N-Acetyl cysteine attenuates the sarcopenia and muscle apoptosis induced by chronic liver disease | |
BR112022011312A2 (pt) | Análise de um analito disposto dentro de um meio | |
Majewski et al. | Spirulina extract improves age-induced vascular dysfunction | |
Zinellu et al. | Highly sensitive simultaneous detection of cultured cellular thiols by laser induced fluorescence‐capillary electrophoresis | |
Chen et al. | Imaging dynamic changes of an intracellular cysteine pool that responds to the stimulation of external oxidative stress | |
ATE475096T1 (de) | Unterscheidung zwischen baktiereller meningitis und viraler meningitis | |
ES2898929T3 (es) | Diagnóstico y tratamiento de alfa-sinucleinopatías | |
Thouvenot et al. | Quantitative proteomic analysis reveals protein expression changes in the murine neuronal secretome during apoptosis | |
DE60229303D1 (de) | Bioäquivalenztest für eisenhaltige formulierungen | |
JPH01210863A (ja) | 精子細胞計数および生存精子細胞の比率、あるいは、これらいずれか一方の高速定量方法ならびにその装置 | |
Fujiki et al. | Homocysteine induced SH-SY5Y apoptosis through activation of NADPH oxidase in U251MG cells | |
WO2002066982A8 (de) | Analyse von modifizierungen und demodifizierungen von proteinen mit ubiquintin-verwandten proteinen mittels fret (fluorescence resonance energy transfer) | |
DE50214753D1 (de) | Vorrichtung zur bestimmung rheologischer eigenschaften | |
CN110441457A (zh) | 一种检测尿液中同型半胱氨酸的方法 | |
Falamas et al. | Monitoring the RNA distribution in human embryonic stem cells using Raman micro-spectroscopy and fluorescence imaging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: WYETH HOLDINGS CORPORATION (US) Free format text: ALTERADO DE: AMERICAN CYANAMID COMPANY |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13 E 25 DA LPI. |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |